9 results on '"Wang, Yan-Yan"'
Search Results
2. Letter: repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma in ideal candidates.
- Author
-
Teng, Yu‐Xian, Zhang, Wan‐Guang, Chan, Anthony Wing‐hung, Chong, Charing Ching Ning, Serenari, Matteo, Wang, Yan‐Yan, Peng, Ning, Huang, Tao, Lu, Shi‐Dong, Liang, Zhi‐Yin, Ma, Liang, and Zhong, Jian‐Hong
- Subjects
CATHETER ablation ,HEPATOCELLULAR carcinoma ,ATRIAL flutter - Abstract
LINKED CONTENT: This article is linked to Tong et al papers. To view these articles, visit https://doi.org/10.1111/apt.17263 and https://doi.org/10.1111/apt.17423 [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Optimizing stage of single large hepatocellular carcinoma
- Author
-
Zhong, Jian-Hong, Pan, Ling-Hui, Wang, Yan-Yan, Cucchetti, Alessandro, Yang, Tian, You, Xue-Mei, Ma, Liang, Gong, Wen-Feng, Xiang, Bang-De, Peng, Ning-Fu, Wu, Fei-Xiang, Li, Le-Qun, Zhong, Jian-Hong, Pan, Ling-Hui, Wang, Yan-Yan, Cucchetti, Alessandro, Yang, Tian, You, Xue-Mei, Liang, Ma, Gong, Wen-Feng, Xiang, Bang-De, Peng, Ning-Fu, Fei-Xiang, Wu, and Le-Qun, Li
- Subjects
Adult ,Male ,Carcinoma, Hepatocellular ,Prognosi ,overall survival ,stage designation ,Observational Study ,hepatic resection ,Follow-Up Studie ,Retrospective Studie ,Hepatectomy ,Humans ,Hospital Mortality ,Neoplasm Staging ,Retrospective Studies ,Medicine (all) ,tumor size ,Liver Neoplasms ,hepatocellular carcinoma ,Middle Aged ,Prognosis ,Survival Analysis ,Tumor Burden ,Liver Neoplasm ,Female ,Survival Analysi ,Human ,Research Article ,Follow-Up Studies - Abstract
This study aims to refine the designation for single hepatocellular carcinoma (HCC) >5 cm by comparing the postresection prognosis of these patients with those who have a single-tumor â¤5 cm and those with stage B. Patients with a single-tumor were classified into subgroups based on diameter. Of the 1132 patients analyzed, 426 had a single-tumor >2 and â¤5 cm; 229, a single-tumor >5 and â¤8 cm; 52, a single-tumor >8 and < 10 cm; 150, a single-tumor â¥10 cm; and 275, stage B. Hospital mortality and complications increased with tumor size among the single-tumor subgroups and median survival decreased with increasing of tumor size. Overall survival (OS) among patients with a single-tumor >5 cm was significantly lower than among patients with a single-tumor >2 and â¤5 cm (P ⤠.001), but significantly higher than among patients with clearly stage B (P ⤠.001). Patients with a single-tumor >5 and â¤8 cm showed lower OS than patients with a single-tumor >2 and â¤5 cm (P < .001). Patients with a single-tumor >8 and 5 and â¤8 cm (P = .033 and.006), and similar OS to patients with stage B (P = .323). Patients with a single-tumor >5 and â¤8 cm may be assigned to a new stage between early and intermediate. Patients with a single-tumor >8 cm may be assigned to intermediate stage.
- Published
- 2017
4. Combination Of ALBI And APRI To Predict Post-Hepatectomy Liver Failure After Liver Resection For HBV-Related HCC Patients.
- Author
-
Mai, Rong-yun, Wang, Yan-yan, Bai, Tao, Chen, Jie, Xiang, Bang-de, Wu, Guo-bin, Wu, Fei-xiang, Li, Le-qun, and Ye, Jia-zhou
- Subjects
LIVER failure ,HEPATITIS B virus ,PORTAL vein surgery ,RECEIVER operating characteristic curves ,LIVER surgery ,HEPATOCELLULAR carcinoma - Abstract
Purpose: Post-hepatectomy liver failure (PHLF) is a severe complication in hepatocellular carcinoma (HCC) patients who have undergone hepatectomy. This research aimed to investigate the combination of albumin–bilirubin (ALBI) score and aspartate aminotransferase-platelet ratio index (APRI) as a novel approach in predicting PHLF risk in hepatitis B virus (HBV)-related HCC patients. Patients and methods: HBV-related HCC patients who underwent hepatectomy from January 2006 to October 2013 were enrolled in this study. A novel model was constructed using a combination of ALBI and APRI scores to predict PHLF risk, and the prognostic value of the model was evaluated and compared with Child-Pugh (C-P) grade, ALBI score and APRI score. Results: A total of 1,055 HCC patients were retrospectively studied, which included 151 experienced PHLF. Univariable and multivariate analyses showed that the ALBI and APRI scores were independent predictors of PHLF. The area under the ROC curve (AUC) of the ALBI score, APRI score, and C-P grade was 0.717, 0.720, and 0.602, respectively, with AUC (ALBI) > AUC (C-P) (P <0.001) and AUC (APRI) > AUC (C-P) (P <0.001). After ALBI was associated with APRI, the AUC (ALBI-APRI) was 0.766, and AUC (ALBI-APRI) > AUC (ALBI) (P <0.001), AUC (ALBI-APRI) > AUC (APRI) (P =0.047). Our results indicated that ALBI and APRI scores had higher discriminatory abilities than C-P grade in predicting the risk of PHLF, and the ALBI-APRI model could enhance the capability of predicting PHLF compared to ALBI or APRI alone. Conclusion: ALBI-APRI score is a novel and effective predictive model of PHLF for HBV-related HCC patients, and its accuracy in predicting the risk of PHLF is better than that of C-P, ALBI and APRI scores. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion.
- Author
-
Wang, Yan-Yan, Wang, Li-Jun, Xu, Da, Liu, Ming, Wang, Hong-Wei, Wang, Kun, Zhu, Xu, and Xing, Bao-Cai
- Subjects
- *
CHEMOEMBOLIZATION , *HEPATOCELLULAR carcinoma , *PROPENSITY score matching , *PROGRESSION-free survival , *CANCER invasiveness , *LIVER cancer - Abstract
Abstract Background Microvascular invasion (MVI) is a powerful predictor of recurrence in patients who undergo liver resection for hepatocellular carcinoma (HCC). This study aimed to evaluate the efficacy of postoperative adjuvant transarterial chemoembolization (PA-TACE) in HCC patients with MVI, and further select potential patients benefitting from PA-TACE. Methods Patients who had HCC with MVI and underwent liver resection between September 2004 and December 2015 were identified for further analysis. Overall survival (OS) and disease-free survival (DFS) were compared between patients treated with and without PA-TACE. Propensity score matching analysis was used to minimize inter-group differences. Results A total of 176 patients with HCC and MVI were included. In both the entire and propensity-matched cohorts, OS and DFS were higher in PA-TACE group than non-TACE group (all P < 0.05). In subgroup analyses, PA-TACE showed efficacy in improving OS and DFS in HCC patients at early stage beyond Milan criteria and intermediate stage, but not in patients within Milan criteria. Multivariable analysis identified PA-TACE as a significantly favorable factor of OS and DFS for patients beyond Milan criteria, but not for those within Milan criteria. Conclusion PA-TACE could be beneficial for patients who have HCC with MVI beyond Milan criteria, but not for those within Milan criteria. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure.
- Author
-
Xiang, Xiao, Qin, Hong‐Gui, You, Xue‐Mei, Wang, Yan‐Yan, Qi, Lu‐Nan, Ma, Liang, Xiang, Bang‐De, Zhong, Jian‐Hong, and Li, Le‐Qun
- Subjects
LIVER cancer ,HEPATITIS B treatment ,AFLATOXINS ,MESSENGER RNA ,DETOXIFICATION (Alternative medicine) ,PROGNOSIS - Abstract
This study aims to clarify the relationship and mechanism between expression of autophagy-related protein P62 and prognosis of patients with hepatocellular carcinoma ( HCC) involving chronic hepatitis B virus ( HBV) infection and aflatoxin B1 ( AFB1) exposure. HCC patients who underwent resection were divided into three groups: HBV(+)/ AFB1(+) ( n = 26), HBV(+)/ AFB1(−) ( n = 68), and HBV(−)/ AFB1(−) ( n = 14). The groups were compared in terms of mRNA and protein levels of P62, disease-free survival ( DFS), and overall survival ( OS) and the expression of NRF2, Nqo1, and AKR7A3 in P62 high-expression and low-expression group. HBV(+)/ AFB1(+) group has lower DFS and OS, and higher P62 expression than in the other two groups. P62 expression generally correlated with elevated NRF2 and Nqo1 expression, and reduced AKR7A3 expression. Patients expressing high levels of P62 showed significantly lower DFS and OS rates than patients expressing low levels. HCC involving HBV infection and AFB1 exposure is associated with relatively high risk of tumor recurrence, and this poor prognosis may relate to high P62 expression. High P62 expression activates the NRF2 pathway, promotes tumor recurrence. The downregulation of AKR7A3 also reduced liver detoxification of aflatoxin B1. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Impact of Diabetes Mellitus on the Prognosis of Patients with Hepatocellular Carcinoma after Curative Hepatectomy.
- Author
-
Wang, Yan-Yan, Huang, Shan, Zhong, Jian-Hong, Ke, Yang, Guo, Zhe, Liu, Jia-Qi, Ma, Liang, Li, Hang, Ou, Bing-Ning, and Li, Le-Qun
- Subjects
- *
LIVER cancer , *DIABETES complications , *HEPATECTOMY , *RETROSPECTIVE studies , *PROPORTIONAL hazards models , *PROGNOSIS - Abstract
: Background: The influence of diabetes mellitus (DM) on the prognosis of patients with hepatocellular carcinoma (HCC) remains controversial. Here we investigated the impact of DM on the prognosis of such patients after curative hepatectomy. Methods: A consecutive cohort of 505 patients with HCC (134 with DM, 371 without) underwent curative hepatectomy were retrospectively evaluated. Postoperative morbidity and mortality, overall survival (OS) and disease-free survival (DFS) were compared between patients with or without DM. Independent prognostic predictors were identified using the Cox proportional hazards model. Results: Patients with or without DM showed similar morbidity and 30- and 90- day mortality after curative hepatectomy (all P>0.05), as well as similar DFS at 1, 3, 5 years (P = 0.781). However, the group of patients with DM showed significantly lower OS at 1, 3, 5 years than the group without DM (P = 0.038). Similar results were obtained in the propensity-matched cohort. Cox multivariate analysis identified DM as an independent predictor of poor OS, but not of poor DFS. We repeat compared OS and DFS for DM and non-DM subgroups defined according to the presence or absence of hepatitis B virus infection and cirrhosis. Similar results were obtained in all subgroups except the non-cirrhotic subgroup which showed patients with and without DM had similar OS. Conclusions: DM does not significantly affect the postoperative morbidity or mortality or the DFS of patients with HCC after curative hepatectomy. It is, however, associated with significantly lower OS, especially in patients with cirrhosis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Hepatic Resection Is Safe and Effective for Patients with Hepatocellular Carcinoma and Portal Hypertension.
- Author
-
Zhong, Jian-Hong, Li, Hang, Xiao, Nan, Ye, Xin-Ping, Ke, Yang, Wang, Yan-Yan, Ma, Liang, Chen, Jie, You, Xue-Mei, Zhang, Zhi-Yuan, Lu, Shi-Dong, and Li, Le-Qun
- Subjects
LIVER cancer ,PORTAL hypertension ,LIVER cancer patients ,HEPATECTOMY ,TREATMENT effectiveness ,MORTALITY ,RETROSPECTIVE studies ,THERAPEUTICS - Abstract
Background & Aims: Official guidelines do not recommend hepatic resection (HR) for patients with hepatocellular carcinoma (HCC) and portal hypertension (PHT). This study aims to investigate the safety and efficacy of HR for patients with HCC and PHT. Methods: Mortality and survival after HR were analyzed retrospectively in a consecutive sample of 1738 HCC patients with PHT (n = 386) or without it (n = 1352). To assess the robustness of findings, we repeated the analysis using propensity score-matched analysis. We also comprehensively searched the PubMed database for studies evaluating the efficacy and safety of HR for patients with HCC and PHT. Results: The 90-day mortality rate was 6.7% among those with PHT and 2.1% among those without it (P<.001). Patients without PHT had a survival benefit over those with PHT at 1, 3, and 5 years (96% vs 90%, 75% vs 67%, 54% vs 45%, respectively; P = .001). In contrast, PHT was not associated with worse short- or long-term survival when only propensity score-matched pairs of patients and those with early-stage HCC or those who underwent minor hepatectomy were included in the analysis (all P>.05). Moreover, the recurrence rates were similar between the two groups. Consistent with our findings, all 9 studies identified in our literature search reported HR to be safe and effective for patients with HCC and PHT. Conclusions: HR is safe and effective in HCC patients with PHT and preserved liver function. This is especially true for patients who have early-stage HCC or who undergo minor hepatectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Luteoloside Suppresses Proliferation and Metastasis of Hepatocellular Carcinoma Cells by Inhibition of NLRP3 Inflammasome.
- Author
-
Fan, Shao-hua, Wang, Yan-yan, Lu, Jun, Zheng, Yuan-lin, Wu, Dong-mei, Li, Meng-qiu, Hu, Bin, Zhang, Zi-feng, Cheng, Wei, and Shan, Qun
- Subjects
- *
CELL proliferation , *METASTASIS , *LIVER cancer , *CANCER cells , *CASPASES , *INTERLEUKIN-1 , *ANTINEOPLASTIC agents - Abstract
The inflammasome is a multi-protein complex which when activated regulates caspase-1 activation and IL-1β secretion. Inflammasome activation is mediated by NLR proteins that respond to stimuli. Among NLRs, NLRP3 senses the widest array of stimuli. NLRP3 inflammasome plays an important role in the development of many cancer types. However, Whether NLRP3 inflammasome plays an important role in the process of hepatocellular carcinoma (HCC) is still unknown. Here, the anticancer effect of luteoloside, a naturally occurring flavonoid isolated from the medicinal plant Gentiana macrophylla, against HCC cells and the underlying mechanisms were investigated. Luteoloside significantly inhibited the proliferation of HCC cells in vitro and in vivo. Live-cell imaging and transwell assays showed that the migration and invasive capacities of HCC cells, which were treated with luteoloside, were significantly inhibited compared with the control cells. The inhibitory effect of luteoloside on metastasis was also observed in vivo in male BALB/c-nu/nu mouse lung metastasis model. Further studies showed that luteoloside could significantly reduce the intracellular reactive oxygen species (ROS) accumulation. The decreased levels of ROS induced by luteoloside was accompanied by decrease in expression of NLRP3 inflammasome resulting in decrease in proteolytic cleavage of caspase-1. Inactivation of caspase-1 by luteoloside resulted in inhibition of IL-1β. Thus, luteoloside exerts its inhibitory effect on proliferation, invasion and metastasis of HCC cells through inhibition of NLRP3 inflammasome. Our results indicate that luteoloside can be a potential therapeutic agent not only as an adjuvant therapy for HCC, but also, in the control and prevention of metastatic HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.